AMAbraham S. Meijnikman

Abraham S. Meijnikman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abraham S. Meijnikman has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Max Nieuwdorp

    Amsterdam UMC

    3 shared publications
  • H. Herrema

    Department of Experimental Vascular Medicine Amsterdam UMC Amsterdam The Netherlands

    2 shared publications
  • O. Aydin

    From the Department of Vascular Medicine Amsterdam UMC Amsterdam The Netherlands

    2 shared publications
  • V. Tremaroli

    Wallenberg Laboratory Department of Molecular and Clinical Medicine Institute of Medicine University of Gothenburg Goteborg Sweden

    2 shared publications
  • A. K. Groen

    Department of Experimental Vascular Medicine Amsterdam UMC Amsterdam The Netherlands

    1 shared publication
  • A. Lundqvist

    Wallenberg Laboratory Department of Molecular and Clinical Medicine Institute of Medicine University of Gothenburg Goteborg Sweden

    1 shared publication

Latest Publications

  • Open Access

    Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals

    by Oluwatomisono I. Akinrimisi, Mijra Koning, Jean L. J. M. Scheijen, Abraham S. Meijnikman, Daniko P. Sindhunata, Sjoerd Bruin, Arnold van de Laar, Rutger Franken, Yair Acherman, Victor E. A. Gerdes, et al.

    Introduction: Methylglyoxal (MGO) is a very reactive compound that modifies proteins, forming advanced glycation end products (AGEs) and activating inflammatory pathways. Elevated MGO levels have been linked to various diseases, including type 2 diabetes and atherosclerosis. However, the role of MGO and other glycating agents in the progression of liver fibrosis in the setting of metabolic dysfunction associated steatotic liver disease (MASLD) is poorly understood. Methods: This study explores the relationship between plasma MGO levels and related dicarbonyls (glyoxal (GO) and 3‐deoxyglucosone (3‐DG)), which are measured using ultra‐high‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS), and liver fibrosis assessed via histological liver biopsy scoring and the Fibrosis‐4 (FIB‐4) Index. The study population comprised 264 severely obese individuals due to undergo bariatric surgery, a subset from the BARIA cohort (22% type 2 diabetes; 77% females; median age 47 (IQR: 39–54 years); BMI 39 (IQR: 36–41 kg/m 2 )). Results: MGO levels were significantly higher in individuals with type 2 diabetes compared with individuals without type 2 diabetes, with a median of 288 nmol/L (257–334 nmol/L) and 238 (212–279 nmol/L) respectively. MGO levels were higher in males compared with females, with a median of 267 (236–301 nmol/L) and 245 (214–288 nmol/L) respectively. Similar results were found for GO and 3DG. Higher plasma MGO, GO and 3DG levels were significantly associated with the FIB‐4 Index (MGO, rho = 0.21, p < 0.01), (GO, rho = 0.29, p < 0.01), (3DG, rho = 0.25, p < 0.05). Using linear regression models, the association between MGO and the FIB‐4 Index remained significant after adjustment for age (years), sex, BMI, sub‐cohort, smoking status, alcohol consumption, hypertension, HOMA‐IR, HbA1c and fasting glucose levels. Using ordinal logistic regression models, MGO and GO were also associated with liver fibrosis scoring from biopsy before and after adjustment for confounders (Age (years), sex, BMI, sub‐cohort, smoking status, alcohol consumption, hypertension, HOMA‐IR, HbA1c and fasting glucose levels). Notably, the relationships remained significant in individuals without type 2 diabetes and after adjusting for HbA1c and fasting glucose levels. No significant associations were observed between MGO, GO, or 3DG and steatosis or inflammation histology scores after adjustment for confounders. Conclusion: This study shows the potential role of dicarbonyl stress, particularly MGO, in liver fibrosis among obese individuals, highlighting its significance as an independent contributor to liver damage and a potential therapeutic target.


  • Open Access

    Fecal microbiota transplantation does not alter bacterial translocation and visceral adipose tissue inflammation in individuals with obesity

    by Guido J. Bakker, Abraham S. Meijnikman, Torsten P. Scheithauer, Mark Davids, Ömrüm Aydin, Thomas C. C. Boerlage, L. Maurits de Brauw, Arnold W. van de Laar, Victor E. Gerdes, Albert K. Groen, et al.

    Aims: Visceral adipose tissue inflammation is a fundamental mechanism of insulin resistance in obesity and type 2 diabetes. Translocation of intestinal bacteria has been suggested as a driving factor for the inflammation. However, although bacterial DNA was detected in visceral adipose tissue of humans with obesity, it is unclear to what extent this is contamination or whether the gut microbiota is causally involved. Effects of fecal microbiota transplantation (FMT) on bacterial translocation and visceral adipose tissue inflammation in individuals with obesity and insulin resistance were assessed.Material and Methods: Eight individuals with clinically severe obesity (body mass index [BMI] >35 kg/m2) and metabolic syndrome received lean donor FMT 4 weeks prior to elective bariatric surgery. The participants were age‐, sex‐, and BMI‐matched to 16 controls that underwent no fecal transplantation. Visceral adipose tissue was collected during surgery. Bacterial translocation was assessed by 16S rRNA gene sequencing of adipose tissue and feces. Pro‐inflammatory cytokine expression and histopathological analyses of visceral adipose tissue were performed to assess inflammation.Results: Fecal microbiota transplantation significantly altered gut microbiota composition. Visceral adipose tissue contained a very low quantity of bacterial DNA in both groups. No difference in visceral bacterial DNA content between groups was observed. Also, visceral expression of pro‐inflammatory cytokines and macrophage infiltration did not differ between groups. No correlation between inflammatory tone and bacterial translocation was observed.Conclusions: Visceral bacterial DNA content and level of inflammation were not altered upon FMT. Thus, bacterial translocation may not be the main driver of visceral adipose tissue inflammation in obesity.


  • Open Access

    A systems biology approach to understand gut microbiota and host metabolism in morbid obesity: design of the BARIA Longitudinal Cohort Study

    by C. C. Van Olden, A. W. Van de Laar, A. S. Meijnikman, O. Aydin, N. Van Olst, J. B. Hoozemans, L. M. De Brauw, S. C. Bruin, Y. I. Z. Acherman, J. Verheij, et al.

    Introduction: Prevalence of obesity and associated diseases, including type 2 diabetes mellitus, dyslipidaemia and non‐alcoholic fatty liver disease (NAFLD), are increasing. Underlying mechanisms, especially in humans, are unclear. Bariatric surgery provides the unique opportunity to obtain biopsies and portal vein blood‐samples.Methods: The BARIA Study aims to assess how microbiota and their metabolites affect transcription in key tissues and clinical outcome in obese subjects and how baseline anthropometric and metabolic characteristics determine weight loss and glucose homeostasis after bariatric surgery. We phenotype patients undergoing bariatric surgery (predominantly laparoscopic Roux‐en‐Y gastric bypass), before weight loss, with biometrics, dietary and psychological questionnaires, mixed meal test (MMT) and collect fecal‐samples and intra‐operative biopsies from liver, adipose tissues and jejunum. We aim to include 1500 patients. A subset (approximately 25%) will undergo intra‐operative portal vein blood‐sampling. Fecal‐samples are analyzed with shotgun metagenomics and targeted metabolomics, fasted and postprandial plasma‐samples are subjected to metabolomics, and RNA is extracted from the tissues for RNAseq‐analyses. Data will be integrated using state‐of‐the‐art neuronal networks and metabolic modeling. Patient follow‐up will be ten years.Results: Preoperative MMT of 170 patients were analysed and clear differences were observed in glucose homeostasis between individuals. Repeated MMT in 10 patients showed satisfactory intra‐individual reproducibility, with differences in plasma glucose, insulin and triglycerides within 20% of the mean difference.Conclusion: The BARIA study can add more understanding in how gut‐microbiota affect metabolism, especially with regard to obesity, glucose metabolism and NAFLD. Identification of key factors may provide diagnostic and therapeutic leads to control the obesity‐associated disease epidemic.


  • Distinct differences in gut microbial composition and functional potential from lean to morbidly obese subjects

    by A. S. Meijnikman, O. Aydin, A. Prodan, V. Tremaroli, H. Herrema, E. Levin, Y. Acherman, S. Bruin, V.E. Gerdes, F. Backhed, et al.

    Introduction: The gut microbiome may contribute to the development of obesity. So far, the extent of microbiome variation in people with obesity has not been determined in large cohorts and for a wide range of body mass index (BMI). Here, we aimed to investigate whether the faecal microbial metagenome can explain the variance in several clinical phenotypes associated with morbid obesity.Methods: Caucasian subjects were recruited at our hospital. Blood pressure and anthropometric measurements were taken. Dietary intake was determined using questionnaires. Shotgun metagenomic sequencing was performed on faecal samples from 177 subjects.Results: Subjects without obesity (n = 82, BMI 24.7 ± 2.9 kg m−2) and subjects with obesity (n = 95, BMI 38.6 ± 5.1 kg m−2) could be clearly distinguished based on microbial composition and microbial metabolic pathways. A total number of 52 bacterial species differed significantly in people with and without obesity. Independent of dietary intake, we found that microbial pathways involved in biosynthesis of amino acids were enriched in subjects with obesity, whereas pathways involved in the degradation of amino acids were depleted. Machine learning models showed that more than half of the variance in body fat composition followed by BMI could be explained by the gut microbiome, composition and microbial metabolic pathways, compared with 6% of variation explained in triglycerides and 9% in HDL.Conclusion: Based on the faecal microbiota composition, we were able to separate subjects with and without obesity. In addition, we found strong associations between gut microbial amino acid metabolism and specific microbial species in relation to clinical features of obesity.